Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HYP-2090PTSA in KRAS G12C-mutated advanced solid tumors
CTR20234061Phase 2Active
- Sponsor
- Huiyu Haiyue
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of HY-0002a in Nonhematologic neoplasms (2 arms), sponsored by Huiyu Haiyue. Primary endpoints: Dose-limiting toxicity, Safety and tolerability and 1 more. Started Dec 2023; status: active.
02
Drugs
HY-0002a
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20234061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234061.